Form 4: Director Acquires TriSalus Life Sciences Stock
Insider Transaction Filing
Director Gary B. Gordon acquired 10,000 shares of common stock in TriSalus Life Sciences, Inc. on May 15, 2026.
Summary
- Director Gary B. Gordon acquired 10,000 shares of TriSalus Life Sciences, Inc. common stock on May 15, 2026.
- The acquisition was made at a price of $2.46 per share.
- Following this transaction, Gordon beneficially owns 72,510 shares of common stock.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents an insider's investment, but it does not provide new operational or financial performance data.
Positives
- Director's investment signals confidence in the company.
- Acquisition of 10,000 shares at $2.46 per share.
Future Outlook
No forward-looking statements or guidance were provided in this filing.
Industry Context
StockSavvy.ai notes that insider transactions, such as this stock acquisition by a director, are often closely watched by investors as they can indicate management's belief in the company's future prospects.
Stakeholder Impact
- Shareholders may view this acquisition positively as a sign of director confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 05/15/2026 | Transaction Date (Acquisition of common stock) |
| 05/18/2026 | Date of Report Signature |
Keywords
TriSalus Life Sciences, TLSI, Form 4, Insider Trading, Stock Acquisition, Director, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.